Sutro drops as portfolio review leads to downgrades
Source: SeekingAlpha
2025-03-14 08:40:18 ET
More on Sutro Biopharma
- Sutro Biopharma: I Don't Buy That Their Pipeline Is Worthless
- Sutro Biopharma rises after market hours on portfolio review, restructuring
- Seeking Alpha’s Quant Rating on Sutro Biopharma
- Historical earnings data for Sutro Biopharma
- Financial information for Sutro Biopharma
Read the full article on Seeking Alpha
For further details see:
Sutro drops as portfolio review leads to downgrades
Sutro Biopharma Inc.
NASDAQ: STRO
STRO Trading
1.35% G/L:
$40.11 Last:
145,027 Volume:
$43.85 Open:
STRO Latest News
May 14, 2026 04:05:00 pm
Sutro Biopharma Reports First Quarter 2026 Financial Results and Business HighlightsApril 19, 2026 07:45:00 pm
Sutro Biopharma Presents Promising Preclinical Data Across its Pipeline of Next-Generation Single and Dual-Payload ADC Programs at AACR 2026March 23, 2026 04:05:00 pm
Sutro Biopharma Reports Full Year 2025 Financial Results and Business HighlightsSTRO Stock Data
$132,896,188
8,207,042
0.54%
38
N/A
Biotechnology & Life Sciences
Healthcare
US
South San Francisco
